In vivo studies will be important to fully validate the therapeutic potential of BRD4780 and TMED9 inhibition and would further contribute to our understanding of BRD4780′s pharmacokinetics, biodistribution, and ability to cross the BBB, as well as its impact on tumor growth, survival, and the immune response. Here, TMED9 is linked to neoplasm.